Optimize dose, detect variable pharmocokinetics, and monitor patient adherence.
Prior to testing patient should have had uninterrupted imatinib therapy for at least 29 days with no change in dose or treatment for at least 8 days. Blood draw should be performed immediately prior to the next scheduled dose.
Plasma, Pre-dose (Trough) Draw - At a Steady State Concentration, in K2EDTA (Lavender or Pink) or Lithium Heparin (Green)
Separate from cells within 48 hours of collection. Centrifuge the whole blood for a minimum of 10 minutes to separate the plasma from cells. Carefully draw off the plasma starting from the top of the plasma layer, avoiding the cell layer (contamination of plasma with blood cells may interfere with results). Transfer 1 mL plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Whole blood, gel separator tubes, light blue (citrate), or yellow top tubes.
Ambient: 7 days; Refrigerated: 30 days; Frozen: 30 days
The therapeutic range is based on plasma pre-dose (trough) draw at steady-state concentration. Concentrations above 1000 ng/mL in chronic myelogenous leukemia (CML) patients, and above 1100 ng/mL in gastrointestinal stromal tumor (GIST) patients are statistically associated with an improved response.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
- Imatinib Mesylate